Asenapine

證據等級: L5

預測適應症: 10 個

Asenapine: From Schizophrenia/Bipolar Disorder to Retinal Dystrophy with Extraocular Anomalies

One-Sentence Summary

Asenapine is a second-generation atypical antipsychotic approved internationally for the treatment of schizophrenia and acute manic or mixed episodes associated with Bipolar I Disorder. The TxGNN model predicts it may be effective for Retinal Dystrophy with or without Extraocular Anomalies, with 0 clinical trials and 15 publications (indirectly related, none directly validating this use) currently found in the evidence search. This prediction is currently unsupported by direct clinical evidence and requires mechanistic and preclinical validation before further development.

Quick Overview

Item	Content
Original Indication	Schizophrenia; Acute manic/mixed episodes of Bipolar I Disorder
Predicted New Indication	Retinal Dystrophy with or without Extraocular Anomalies
TxGNN Prediction Score	99.77%
Evidence Level	L5
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, asenapine is a multireceptor-active atypical antipsychotic with high affinity for serotonin (5-HT2A, 5-HT2C), dopamine (D2–D4), histamine (H1), and adrenergic (α1, α2) receptors. It is established for central nervous system conditions — specifically psychotic and affective disorders — and is administered sublingually due to extensive first-pass metabolism.

The connection between asenapine and retinal dystrophy with extraocular anomalies is not immediately apparent from established pharmacology. Retinal dystrophies are typically inherited genetic disorders affecting photoreceptors, retinal pigment epithelium, or associated neurodevelopmental pathways (e.g., KIF21A, TUBB3 mutations in congenital fibrosis of extraocular muscles). TxGNN may have identified indirect network-level associations — such as shared neuronal signaling cascades, ion channel regulation, or overlapping developmental gene expression patterns — linking antipsychotic receptor targets to ocular tissue biology.

The 15 retrieved publications span general ophthalmological topics (congenital cranial dysinnervation disorders, extraocular muscle anomalies, orbital pathologies) rather than directly investigating asenapine in retinal dystrophy. This literature gap underscores that the TxGNN prediction is exploratory and hypothesis-generating at this stage. Independent mechanistic and preclinical studies would be required to assess biological plausibility before any clinical translation can be considered.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

⚠️ Important Note: The publications below were retrieved based on keyword overlap with “extraocular anomalies” in the disease name. None directly study asenapine for retinal dystrophy. They are provided as background context on the disease landscape only.

PMID	Year	Type	Journal	Key Findings
33806565	2021	Original Study	Int J Mol Sci	Optic nerve and retinal abnormalities in congenital fibrosis of extraocular muscles (CFEOM); KIF21A/TUBB3 mutations may extend beyond oculomotor dysinnervation to retinal ganglion cells
38321238	2024	Review	Pediatric Radiology	Pediatric orbital and ocular pathologies including retinopathy of prematurity, Coats disease, morning glory disc anomaly, and optic disc drusen
7035111	1981	Review	Documenta Ophthalmologica	Wagner-Stickler syndrome: vitreoretinal degeneration with myopia, cataract, retinal detachment, and extraocular manifestations including sensorineural deafness
24932988	2014	Review	Am J Ophthalmol	Proposed unifying theory for maculopathy pathogenesis in cavitary optic disc anomalies and rational treatment approach
38249493	2023	Review	Taiwan J Ophthalmol	Congenital anomalies of lens shape, including association with anterior segment dysgenesis and persistent fetal vasculature
30196776	2018	Review	J Binocular Vis Ocular Motility	Congenital cranial dysinnervation disorders (CCDDs): primary defects of cranial nucleus/nerve development with limitations of ocular motility
24413161	2014	Case Report	J Neuro-Ophthalmology	Isolated trochlear-oculomotor synkinesis in a 6-year-old; discussion of congenital cranial dysinnervation disorder pathophysiology
22241537	2012	Review	Klin Monatsbl Augenheilkd	Simple congenital ptosis: levator muscle dystrophy and fibrosis; frequently associated with refractive errors and binocular vision disturbance
9416661	1997	Review	Semin Ultrasound CT MR	Orbital infections and sinusitis-related cellulitis; five-stage classification; systemic predisposing conditions including diabetes and malignancy
20127583	2010	Review	Semin Neurology	Systematic clinical approach to diplopia arising from ocular, neurologic, or extraocular muscle disorders

Safety Considerations

Drug Interactions: Asenapine has 238 known drug interactions (source: DDInter). The following are of greatest clinical significance:

Major Interactions (highest risk):

Interacting Drug	Level	Clinical Concern
Bupropion	Major	Additive CNS effects; potential lowering of seizure threshold
Morphine	Major	Additive CNS and respiratory depression
Cisapride	Major	Risk of QT interval prolongation and serious cardiac arrhythmia

Selected Moderate Interactions (representative sample):

Interacting Drug	Category
Epinephrine	Cardiovascular: risk of alpha-blockade reversal leading to hypotension
Clarithromycin	Pharmacokinetic: CYP enzyme-mediated interaction
Metformin, Acarbose, Pioglitazone, Canagliflozin, Alogliptin, Chlorpropamide	Metabolic: antipsychotic-associated glucose dysregulation may compromise glycemic control
Atropine, Hyoscyamine	Additive anticholinergic/antimuscarinic effects
Cimetidine, Famotidine	H2 antagonist interactions
Loperamide, Bisacodyl, Castor oil	GI motility-related interactions

For complete warnings and contraindications, please refer to the official prescribing information (package insert). TFDA/CDSCO-specific monograph data is currently unavailable for this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model assigns a high confidence score (99.77%) to asenapine for retinal dystrophy with extraocular anomalies, but this prediction is currently at Evidence Level L5 — no clinical trials exist for this indication and no literature directly connects asenapine to retinal dystrophy pathobiology. Additionally, asenapine is not marketed in India, which further limits near-term translational feasibility.

To proceed, the following is needed:

Mechanism of action validation: Obtain full MOA data (DrugBank API or primary literature) to identify whether any known asenapine receptor targets (5-HT2A, D2–D4, H1, α-adrenergic) have established roles in retinal neurophysiology or photoreceptor development
Preclinical evidence: Commission or identify animal model or in vitro studies evaluating asenapine’s effects on retinal pigment epithelium, photoreceptors, or relevant neurodevelopmental pathways
Pathway analysis: Conduct knowledge graph pathway tracing to understand which specific biological links TxGNN used to generate this prediction (e.g., shared gene targets, disease ontology overlap)
Regulatory safety data: Retrieve TFDA/CDSCO package insert data to complete the safety profile, particularly warnings and contraindications currently listed as unavailable
Comparative prioritization: Consider evaluating the rank 10 prediction (Major Affective Disorder) in parallel, where 4 Phase 3 clinical trials and 19 directly relevant publications already provide L2-level evidence for asenapine — a substantially more actionable development path
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.